Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Calcitonin Gene-Related Peptide (CGRP) and Cluster Headache

Research output: Contribution to journalReviewResearchpeer-review


  1. Standardization of Data for Clinical Use and Research in Spinal Cord Injury

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Expression of the CGRP Family of Neuropeptides and their Receptors in the Trigeminal Ganglion

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. CGRP in rat mesenteric artery and vein - receptor expression, CGRP presence and potential roles

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Cellular distribution of PACAP-38 and PACAP receptors in the rat brain: Relation to migraine activated regions

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Understanding side-effects of anti-CGRP and anti-CGRP receptor antibodies

    Research output: Contribution to journalLetterResearchpeer-review

View graph of relations

Cluster headache (CH) is a severe primary headache with a prevalence of 1/1000 individuals, and a predominance in men. Calcitonin gene-related peptide (CGRP) is a potent vasodilator, originating in trigeminal neurons and has a central role in CH pathophysiology. CGRP and the CGRP receptor complex have recently taken center stage as therapeutic targets for primary headaches, such as migraine. Multiple CGRP and CGRP receptor monoclonal antibodies, as well as small molecule antagonists (gepants) are on their way constituting a new frontier of migraine and possibly CH medication. During a CH attack, there is an activation of the trigeminal-autonomic reflex with the release of CGRP, and inversely if CGRP is administered to a CH patient in an active disease phase, it triggers an attack. Increased levels of CGRP have been found in ipsilateral jugular vein blood during the active phase of CH. This process is hypothesized to have a key role in the intense pain perception and in the associated distinctive vasodilation. So far, clinical tests of CGRP antibodies have been inconclusive in CH patients. This review summarizes the current state of knowledge on the role of CGRP in CH pathology, and as a target for future treatments.

Original languageEnglish
JournalBrain Sciences
Issue number1
Pages (from-to)30
Number of pages16
Publication statusPublished - 6 Jan 2020

    Research areas

  • Antibodies, Genetics, Neurovascular, Receptor, Vasodilator

ID: 59203380